Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis [0.03%]
特瑞普利单抗联合阿昔替尼一线治疗中国晚期肾细胞癌的经济价值：基于模型的成本效益分析
Shuo Kang,Jintuo Yin
Shuo Kang
Objective: The current analysis aimed to evaluate the economic benefit of toripalimab plus axitinib for previously untreated RCC patients from the Chinese healthcare system perspective. ...
Barriers to digital endpoints in data collection in low and middle-income countries [0.03%]
低收入和中等收入国家在数据收集过程中采用数字终点的障碍
Ahmad Z Al Meslamani
Ahmad Z Al Meslamani
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer [0.03%]
达匹西利和阿贝西利联合芳香化酶抑制剂作为HR阳性/HER2阴性晚期乳腺癌一线治疗的费用效果对比分析
Juan Hong,Tujia Chen,Lihui Ouyang et al.
Juan Hong et al.
Objectives: CDK4/6 inhibitors dalpiciclib and abemaciclib have been approved by the Chinese National Medical Products Administration as first-line treatment for postmenopausal females with hormone receptor-positive (HR+) ...
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system [0.03%]
数据处理算法的发展，用于计算囊性纤维化成人吸入治疗的依从性- CFHealthHub学习健康系统中的多中心观察研究
Robert D Sandler,Lana Lai,Sophie Dawson et al.
Robert D Sandler et al.
Objectives: To develop a robust algorithm to accurately calculate 'daily complete dose counts' for inhaled medicines, used in percent adherence calculations, from electronically-captured nebulizer data within the CFHealth...
Health-related quality of life measured using the EQ-5D-3L: iranian population norms [0.03%]
使用EQ-5D-3L测量的健康相关生活质量：伊朗人群标准
Abdoreza Mousavi,Ali Akbari Sari,Fakhraddin Daastari et al.
Abdoreza Mousavi et al.
Background: Normative values are valuable for comparing a specific population with the general population, making them particularly useful in disease burden studies and cost-effectiveness analysis. The objective of this s...
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study [0.03%]
造口术后两年内的疾病临床和经济负担：一项全国性的丹麦队列研究
Frederikke Bruun Andersen,Jakob Kjellberg,Rikke Ibsen et al.
Frederikke Bruun Andersen et al.
Background: Living with an ostomy is often associated with costly complications. This study examined the burden of illness the first two years after ostomy creation. ...
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation [0.03%]
2022年综合卫生经济学评价报告标准（CHEERS II）声明：经验证的荷兰语翻译
Amber Werbrouck,Esther de Bekker-Grob,Maiwenn Al et al.
Amber Werbrouck et al.
Objectives: This study primarily aimed to develop a validated Dutch translation of the 28 items of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) II. A secondary aim was to provide a worked examp...
Using real world evidence to optimize care: the case of medical cannabis [0.03%]
利用真实世界证据来优化护理：医疗大麻的案例研究
Anne Katrin Schlag,David J Nutt,Michael Lynskey
Anne Katrin Schlag
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review [0.03%]
利用自然语言处理分析来自电子健康记录的癌症人群的非结构化患者报告结果数据的系统性综述
Jin-Ah Sim,Xiaolei Huang,Madeline R Horan et al.
Jin-Ah Sim et al.
Introduction: Patient-reported outcomes (PROs; symptoms, functional status, quality-of-life) expressed in the 'free-text' or 'unstructured' format within clinical notes from electronic health records (EHRs) offer valuable...
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer [0.03%]
用于铂类耐药性复发卵巢癌的贝伐珠单抗生物类似药是否联用化疗的成本效益和药物浪费情况研究
Shih Ping Lai,Shyh-Yau Wang,Agnes Lf Chan et al.
Shih Ping Lai et al.
Introduction: The cost-effectiveness of adding bevacizumab biosimilar with or without chemotherapy (CT) and drug wastage in treating platinum-resistant recurrent ovarian cancer (PRrOC) was assessed. ...